Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial. (December 2022)

• Record Type: Journal Article
• Authors: Fencer, Maria G.; Davis, Catherine H.; Liu, Jieqi; Galan, Mark A.; Spencer, Kristen R.
• Is Part Of: Journal of investigative medicine high impact case reports. Volume 10(2022)
• Publication Date: 2022-12
• Subjects: atezolizumab -- bevacizumab -- sarcomatoid -- hepatocellular carcinoma; Internal medicine -- Periodicals; Medical care -- Periodicals; 616.005
• DOI: 10.1177/23247096221129470
• Languages: English
• ISSNs: 2324-7096

Abstract

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Herein, we describe a case of disease control achieved using the IMbrave regimen in a patient with sarcomatoid hepatocellular carcinoma.